The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of carfilzomib (CFZ) in combination with current agents for relapsed and refractory multiple myeloma (RRMM).
J. Szymonifka
No relevant relationships to disclose
S. Z. Usmani
Consultant or Advisory Role - Onyx (U)
Research Funding - Onyx
R. Sexton
No relevant relationships to disclose
S. Panozzo
No relevant relationships to disclose
B. P. Nair
No relevant relationships to disclose
S. Waheed
No relevant relationships to disclose
Y. Alsayed
No relevant relationships to disclose
J. Crowley
No relevant relationships to disclose
B. Barlogie
No relevant relationships to disclose